Conflict of Interest Disclosures for Society Leadership
Roy L. Silverstein, MD, Medical College of Wisconsin
Equity ownership of Pfizer.
Stephanie J. Lee, MD, MPH, Fred Hutchinson Cancer Research Center
Consultant for Incyte and Pfizer; Honoraria from Mallinckrodt Pharmaceuticals.
Martin S. Tallman, MD, Memorial Sloan Kettering Cancer Center
Consultant for Amgen; Honoraria from 14th Annual Miami Cancer Meeting, 4th International Conference in Leukemia, Danbury Hospital Tumor Board, Hematology Oncology of Indiana, Salzberg Weill Cornall MSKCC Seminar in Hematologic Malignancies, and University of Oklahoma Medical Center Grand Rounds; Membership on a Board or Advisory Committee for Bioline, BioSight, Daiichi-Sankyo, KAHR, Nohla, and Rigel; and Research funding from AbbVie, ADC Therapeutics, AROG, Bioline, Cellerant Therapeutics, and Orsenix.
Robert A. Brodsky, MD, Johns Hopkins University
Honoraria for UpToDate; Membership on a Board or Advisory Committee for Achillion Pharmaceuticals and Apellis; Research funding from Alexion Pharmaceuticals and Apellis.
Mark A. Crowther, MD, McMaster University
Consultant for Hemostasis Reference Laboratories and Shinogi; Equity ownership of Alnylam; Honoraria for Pfizer; Membership on a Board or Advisory Committee for Asahi Kasei, Bayer, BMS, CSL Behring, Daiichi-Sankyo, Octapharma, and Servier Canada; Research funding from Bayer; Speakers Bureau for Alexion and Servier Canada.
Bob Lowenberg, MD, PhD, Erasmus University Medical Center
Consultant for Astex and Clear Creek Bio Ltd; Equity ownership of Frame Pharmaceuticals; Honoraria from Clear Creek Bio Ltd; Membership on a Board or Advisory Committee for AbbVie, Agios Pharmaceuticals, Astellas, Celgene, Celyad, European School of Hematology, Leukemia Cooperative Trial Group HOVON, European Oncology & Haematology, Royal Netherlands Academy of Sciences and Arts, Hoffman-La Roche Ltd, The Netherlands National Comprehensive Cancer Center, and UpToDate.
Blood Deputy Editor
Nancy Berliner, MD, Brigham and Women's Hospital
Consultant for Biogen; Honoraria from UpToDate; Patents & Royalties from Clinical Decision Support; Research funding from Novartis.
Blood Advances Editor-in-Chief
Robert Negrin, MD, Stanford University Medicine
Consultant for Amgen, Applied Stem Cell, Cell Source, Jazz Pharmaceuticals, Regimmune, and UpToDate; Equity ownership of BioEclipse Therapeutics, Cell Source, Formula, and Magenta; Membership on a Board or Advisory Committee for BioEclipse Therapeutics, Formula, Magenta, University of Pennsylvania.
ASH Clinical News Editor-in-Chief
Mikkael Sekeres, MD, MS, Cleveland Clinic
Membership on a Board or Advisory Committee for Celgene and Opsona.
The Hematologist Editor-in-Chief
Laura Michaelis, MD, Medical College of Wisconsin
Equity ownership of Pfizer; Membership on a Board or Advisory Committee for Celgene, Incyte, Jazz Pharmaceuticals, and Novartis; Research funding from Jazz Pharmaceuticals; Speakers Bureau for Celgene.
Martha Liggett, American Society of Hematology
Indicated no conflicts of interest.
Deputy Executive Director
Matthew Gertzog, American Society of Hematology
Equity ownership of Amgen.